Serum erythropoietin levels in patients with central serous chorioretinopathy
Burak Turgut1, Nevin Ilhan2, Fatma Yayla Uyar1, Ulku Celiker1, Tamer Demir1, Suleyman Serdar Koca3
1Fırat University School of Medicine, Department of Ophthalmology, Elazig, Turkey; 2Fırat University School of Medicine, Department of Biochemistry, Elazig, Turkey; 3Fırat University School of Medicine, Department of Interal Medicine, Elazig, Turkey
Objective: To evaluate the levels of erythropoietin (EPO) in the serum in patients with central serous chorioretinopathy (CSC).
Methods: An institutional comperative clinical study. The serum EPO levels were measured with the enzyme-linked immunosorbent assay (ELISA) method, of 15 patients with active CSC (Group 1), 15 patients with inactive CSC (Group 2) and 15 healthy volunteers (Group 3). Kruskal–Wallis variance analysis and Mann–Whitney U test were used for statistical analysis.
Results: The patient and control groups were matched for age and sex. There was no statistically significant variation with regard to age and gender among the groups (P > 0.05). The mean serum EPO concentrations in patients with active CSC (Group 1), inactive CSC (Group 2) and in healthy controls (Group 3) were 11.39 ± 3.01 mlU/mL, 11.79 ± 3.78 mlU/mL and 11.95 ± 3.27 mlU/mL, respectively. There was no significant variation among the serum EPO concentrations of the study groups (P > 0.05).
Conclusion: These findings suggest no role of serum EPO in pathogenesis of CSC.
Keywords: Central serous chorioretinopathy, erythropoietin, serum
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]